Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease

by James F Donohue, Paul W Jones
Published 2011-01-01

Nebulized formoterol: a review of clinical efficacy and safety in COPD

by Nicholas J Gross, James F Donohue
Published 2010-06-01

Nebulized arformoterol: what is its place in the management of COPD?

by Matthew C. Miles, James F. Donohue, Jill A. Ohar
Published 2013-04-01

Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-findin...

by James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler
Published 2017-12-01

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base

by Anthony D. D’Urzo, Dave Singh, James F. Donohue, Kenneth R. Chapman
Published 2019-05-01

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective

by Dave Singh, Anthony D. D’Urzo, James F. Donohue, Edward M. Kerwin
Published 2019-07-01

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III tri...

by Sanjay Sethi, James F. Donohue, Gary T. Ferguson, Chris N. Barnes, Glenn D. Crater
Published 2020-02-01

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

by James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Glenn D. Crater
Published 2020-05-01

Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial

by James F. Donohue, Nicola A. Hanania, Charles Fogarty, Sammy C. Campbell, Mike Rinehart, Kimberly Denis-Mize
Published 2008-08-01

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

by Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi, David Price
Published 2019-03-01

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

by James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater
Published 2019-10-01

Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease

by Roy A. Pleasants, Khosrow Heidari, Jill Ohar, James F. Donohue, Njira Lugogo, Chelsea L. Richard, Sarojina Kanotra, David M. Mannino, Monica Kraft, Winston Liao, Charlie Strange
Published 2019-01-01

Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspe...

by Colin Reisner, Leonardo M. Fabbri, Edward M. Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F. Rabe, Gary T. Ferguson, Fernando J. Martinez, James F. Donohue, Patrick Darken, Earl St. Rose, Chad Orevillo, Shannon Strom, Tracy Fischer, Michael Golden, Sarvajna Dwivedi
Published 2017-08-01